Today: 27 December 2025
Subscribe
Browse Category

FDA News News 15 December 2025 - 26 December 2025

Vera Therapeutics (VERA) Stock Dips in Thin Post‑Christmas Trading as Wall Street Weighs FDA Filing, $300M Raise, and IgA Nephropathy Competition

Vera Therapeutics (VERA) Stock Dips in Thin Post‑Christmas Trading as Wall Street Weighs FDA Filing, $300M Raise, and IgA Nephropathy Competition

Friday, December 26, 2025, 11:17 a.m. ET in New York. In that context—a quiet, low‑liquidity post‑Christmas session with major U.S. indexes hovering near record highs—Vera Therapeutics, Inc. (Nasdaq: VERA) is trading lower midday. Reuters and the AP both describe today’s
26 December 2025
 ·  ·  ·  ·  · 
Altria (MO) Stock After Hours on Dec. 24, 2025: Dividend Deadline, Unusual Options Surge, and FDA Nicotine Pouch Catalyst Before the Next Market Open

Altria (MO) Stock After Hours on Dec. 24, 2025: Dividend Deadline, Unusual Options Surge, and FDA Nicotine Pouch Catalyst Before the Next Market Open

NEW YORK — December 24, 2025: Altria Group, Inc. (NYSE: MO) ended the holiday-shortened Christmas Eve session modestly higher and then ticked up again in limited after-hours trading, as income-focused investors and options traders honed in on one near-term catalyst
25 December 2025
 ·  ·  ·  ·  · 
Reviva Pharmaceuticals (RVPH) Stock Plunges After FDA Calls for Second Phase 3 Trial: News, Forecasts, and Analyst Takeaways on Dec. 24, 2025

Reviva Pharmaceuticals (RVPH) Stock Plunges After FDA Calls for Second Phase 3 Trial: News, Forecasts, and Analyst Takeaways on Dec. 24, 2025

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) is in the spotlight on December 24, 2025 after a sharp selloff driven by a major regulatory development: the U.S. Food and Drug Administration recommended that Reviva run an additional Phase 3 trial for
24 December 2025
 ·  ·  ·  ·  · 
Abbott Laboratories Stock After Hours (ABT): FDA Win, Holiday Trading Dynamics, and What to Watch Before the Dec. 24 Open

Abbott Laboratories Stock After Hours (ABT): FDA Win, Holiday Trading Dynamics, and What to Watch Before the Dec. 24 Open

Abbott Laboratories (NYSE: ABT) finished Tuesday, Dec. 23, 2025, modestly lower, even as fresh headlines reinforced the company’s medical-device momentum heading into a holiday-shortened U.S. trading session on Wednesday, Dec. 24. ABT shares closed at $124.54 (-0.53%) and in after-hours
24 December 2025
 ·  ·  ·  ·  · 
Merck (MRK) Stock After Hours Today (Dec. 23, 2025): Shares Slip Slightly After the Close as Investors Track TrumpRx Pricing Deal, FDA Fast-Track Vouchers, and Fresh Wall Street Targets

Merck (MRK) Stock After Hours Today (Dec. 23, 2025): Shares Slip Slightly After the Close as Investors Track TrumpRx Pricing Deal, FDA Fast-Track Vouchers, and Fresh Wall Street Targets

NEW YORK — Merck & Co., Inc. (NYSE: MRK) ended regular trading Tuesday, December 23, 2025, at $105.04, and eased modestly in after-hours trading to about $104.81 (down roughly 0.2%) as of early evening in New York. Google The move
24 December 2025
 ·  ·  ·  ·  · 
Intuitive Surgical Stock (ISRG) Week Ahead: FDA da Vinci 5 Recall Posting, da Vinci SP Expansion, and Fresh Wall Street Targets Into the Christmas Trading Week

Intuitive Surgical Stock (ISRG) Week Ahead: FDA da Vinci 5 Recall Posting, da Vinci SP Expansion, and Fresh Wall Street Targets Into the Christmas Trading Week

Date: December 21, 2025 (Sunday) Intuitive Surgical, Inc. (NASDAQ: ISRG) heads into the Christmas-shortened trading week with momentum—yet also with two developments investors will likely keep on the radar: a newly posted FDA Class 2 recall entry tied to a
22 December 2025
 ·  ·  ·  ·  · 
Biotech Stocks Today: FDA Fast Track Wins, PDUFA Delays and Deal Flow Move GLUE, ALDX, ADAG, PVLA as XBI and IBB Slide

Biotech Stocks Today: FDA Fast Track Wins, PDUFA Delays and Deal Flow Move GLUE, ALDX, ADAG, PVLA as XBI and IBB Slide

Updated: Tuesday, December 16, 2025 | Early afternoon ET (U.S. stock market) Biotechnology stocks are delivering a classic split-screen session in the U.S. market today: biotech ETFs are slipping, but a handful of single-name biotech movers are swinging sharply on FDA updates, clinical
16 December 2025
 ·  ·  ·  ·  · 
Corcept Therapeutics (CORT) Stock Drops on Dec. 16, 2025: UBS Neutral Call, Relacorilant FDA Catalyst, and Updated Price Targets

Corcept Therapeutics (CORT) Stock Drops on Dec. 16, 2025: UBS Neutral Call, Relacorilant FDA Catalyst, and Updated Price Targets

Corcept Therapeutics Incorporated (NASDAQ: CORT) ended Tuesday, December 16, 2025, sharply lower after a strong 2025 run that had pushed expectations—and valuation—into the spotlight. Shares closed at $79.44, down $7.86 (about 9%) from the prior close, after trading as low
16 December 2025
 ·  ·  ·  ·  · 
uniQure (QURE) Stock Jumps in Pre-Market on Dec. 16, 2025: FDA AMT-130 Uncertainty, Analyst Price Targets, and Key Catalysts Ahead

uniQure (QURE) Stock Jumps in Pre-Market on Dec. 16, 2025: FDA AMT-130 Uncertainty, Analyst Price Targets, and Key Catalysts Ahead

Dec. 16, 2025 — uniQure N.V. (NASDAQ: QURE) is back in the spotlight Tuesday after a notable extended-hours rebound. The gene therapy developer’s shares were highlighted among top pre-market gainers, rising about 15% to roughly $23.50 in early trading, following
16 December 2025
 ·  ·  ·  ·  · 
Sanofi Stock (SAN.PA, SNY) Slides After Tolebrutinib Double Setback: FDA Delay, Trial Miss, and Fresh Analyst Forecasts (Dec. 15, 2025)

Sanofi Stock (SAN.PA, SNY) Slides After Tolebrutinib Double Setback: FDA Delay, Trial Miss, and Fresh Analyst Forecasts (Dec. 15, 2025)

Sanofi stock is under pressure on December 15, 2025, after the French drugmaker disclosed two setbacks tied to its experimental multiple sclerosis (MS) medicine tolebrutinib—a regulatory delay in the U.S. for one progressive MS form and a failed Phase 3
15 December 2025
 ·  ·  ·  ·  · 
1 2 3
Go toTop